Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

The American Society of Clinical Oncology (ASCO) annual meeting highlighted key advancements in cancer treatment, including AstraZeneca's Enhertu significantly stalling HER2-positive metastatic breast cancer progression, Pfizer's Braftovi doubling survival time for aggressive colorectal cancer patients with a specific mutation, and Gilead's Trodelvy, combined with Merck's Keytruda, reducing the risk of aggressive breast cancer worsening by 35%. Conversely, Merck and Daiichi Sankyo withdrew their U.S. application for patritumab deruxtecan after it failed to prolong the lives of lung cancer patients in a late-stage trial, while Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients. Bristol Myers Squibb also announced a deal with BioNTech to develop next-generation cancer immunotherapy.

Analysis

The American Society of Clinical Oncology (ASCO) annual meeting showcased significant developments in oncology, with AstraZeneca's Enhertu demonstrating a substantial extension in progression-free survival for HER2-positive metastatic breast cancer patients to nearly 41 months when used as an initial treatment, potentially reshaping current treatment protocols. Pfizer also reported compelling data for its Braftovi combination in an aggressive form of colorectal cancer, doubling survival time and reducing the risk of death by 51%, prompting an FDA submission for label expansion. Gilead's Trodelvy, in combination with Merck's Keytruda, showed a 35% reduction in the risk of disease worsening for a type of aggressive breast cancer. Conversely, Merck and Daiichi Sankyo faced a setback, withdrawing their U.S. application for the lung cancer candidate patritumab deruxtecan after it failed to extend overall survival, though development will continue for breast cancer. Amgen presented positive late-stage data for Imdelltra in small cell lung cancer, reducing the risk of death by 40% and extending median overall survival by over five months. Beyond ASCO, Bristol Myers Squibb committed up to $11.1 billion to partner with BioNTech on a next-generation cancer immunotherapy, signaling major investment in novel mechanisms. In health-tech, Clairity received FDA approval for its AI breast cancer prediction platform, and Amazon Pharmacy expanded services for Medicare Part D beneficiaries and caregivers, highlighting broader industry trends.

Key Decisions for Investors

• Consider the strengthened oncology portfolios of AstraZeneca (AZN) and Pfizer (PFE), with Enhertu's potential to become a new standard of care in HER2-positive breast cancer and Braftovi's impressive survival benefit in colorectal cancer likely driving near-term value, pending regulatory actions.
• Evaluate Gilead's (GILD) Trodelvy market opportunity in triple-negative breast cancer following positive combination data, while factoring in Merck's (MRK) recent lung cancer drug setback, which emphasizes the challenges in its pipeline diversification efforts beyond Keytruda.
• Recognize the significant potential for BioNTech (BNTX) through its substantial oncology partnership with Bristol Myers Squibb, and note Amgen's positive Imdelltra data reinforcing its lung cancer franchise, a key development from ASCO detailed in the article.
• Monitor the accelerating adoption of AI in healthcare diagnostics, exemplified by Clairity's FDA approval, and Amazon's (AMZN) continued expansion into pharmacy services, as these represent key sectoral shifts with long-term investment implications.